康缘药业: 江苏康缘药业股份有限公司第八届监事会第十二次会议决议公告

Core Viewpoint - The announcement details the resolutions passed during the 12th meeting of the 8th Supervisory Board of Jiangsu Kangyuan Pharmaceutical Co., Ltd., including the approval of the 2024 annual report, supervisory work report, financial settlement report, and other significant matters related to the company's operations and governance [1][2][3]. Group 1: Annual Report and Financials - The Supervisory Board approved the 2024 Annual Report and its summary, confirming that the report accurately reflects the company's operational and financial status for the year [1][2]. - The 2024 Financial Settlement Report was also approved, which objectively and truthfully reflects the company's financial condition and operational results for the year [6]. Group 2: Supervisory Board Activities - The Supervisory Board held six meetings during the reporting period, with all five supervisors present at each meeting, ensuring compliance with legal and regulatory requirements [2][3]. - The Board's activities included oversight of financial management, risk control, and compliance with corporate governance, contributing positively to the company's healthy development and protection of shareholder rights [2][3]. Group 3: Internal Control and Compliance - The Supervisory Board reviewed the internal control evaluation report for 2023, finding that the internal control system is effective and meets relevant requirements, thereby providing good risk prevention and control [5][7]. - The Board confirmed that the company operated in accordance with laws and regulations, with no violations or actions that could harm shareholder interests [3][4]. Group 4: Related Party Transactions - The Board approved the expected related party transactions for 2025, determining that they are necessary for the company's operational development and comply with legal pricing principles [6][8]. - The Board found that all related party transactions were conducted at fair market prices and followed proper decision-making procedures, ensuring no detriment to the company or its shareholders [4][6]. Group 5: Stock Incentive Plan - The Supervisory Board approved the proposal to repurchase and cancel all remaining restricted stocks from the 2022 stock incentive plan, confirming that the process followed appropriate procedures and would not materially affect the company's financial status [8].